Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4369 The predictive value of 68Ga-DOTANOC, 18F-DOPA, and 18F-FDG PET/CT in patients with paragangliomas

Introduction: Paragangliomas (PGLs) are rare neuroendocrine tumours with variable clinical outcomes. Early identification of prognostic markers is essential for effective disease management. PET/CT imaging with 68Ga-DOTANOC, 18F-DOPA, and 18F-FDG offers unique insights into tumour biology, respectively.

Conference:

Presenting Author: Xu J

Authors: Gao J, Xu J, Liang Y, Chen J, Song S,

Keywords: PET/CT, paraganglioma, prognosis,

#4193 Pivotal role of the multidisciplinary tumor board on the management of neuroendocrine neoplasms – Impact of MTB decisions in an ENETS Center of Excellence

Introduction: Multidisciplinary Tumor Board (MTB) meetings are a valuable tool to improve the management of solid tumors. Yet, few evidences regarding the real-world impact of Neuroendocrine Neoplasm (NEN)-dedicated MTBs are available.

Conference:

Presenting Author:

Authors: Maratta M, Vitale A, Occhipinti D, Raia S, Menotti S,

Keywords: multidisciplinary tumor board, neuroendocrine cancer, disease management, patient care,

#3964 Genomic profiling in the randomised controlled phase III COMPOSE trial of Lu-177 edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic-neuroendocrine tumors

Introduction: Targeted radiopharmaceutical therapy (RPT) has demonstrated potential in treatment of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). However, RPT exhibits variable outcomes and lacks tools to predict individual efficacy. To address the latter, a genomic profiling analysis was included in the randomised, controlled, open-label, phase III COMPOSE trial of Lu-177 edotreotide vs. best standard of care (CAPTEM, FOLFOX or everolimus) in patients with well differentiated, aggressive, G2/G3 somatostatin receptor-positive GEP-NETs.

Conference:

Presenting Author:

Authors: Srirajaskanthan R, Capdevila J, Halfdanarson T, Halperin D, Herrmann K,

Keywords: radiopharmaceutical therapy, genomic, Lu-177 edotreotide, gastroenteropancreatic, tumor, neuroendocrine,